Search results for "Brain Injuries"

showing 10 items of 139 documents

Astrocytic Calcium Waves Signal Brain Injury to Neural Stem and Progenitor Cells

2017

Summary Brain injuries, such as stroke or trauma, induce neural stem cells in the subventricular zone (SVZ) to a neurogenic response. Very little is known about the molecular cues that signal tissue damage, even over large distances, to the SVZ. Based on our analysis of gene expression patterns in the SVZ, 48 hr after an ischemic lesion caused by middle cerebral artery occlusion, we hypothesized that the presence of an injury might be transmitted by an astrocytic traveling calcium wave rather than by diffusible factors or hypoxia. Using a newly established in vitro system we show that calcium waves induced in an astrocytic monolayer spread to neural stem and progenitor cells and increase th…

Male0301 basic medicineTime FactorsNotch signaling pathwaySubventricular zonechemistry.chemical_elementBiologyCalciumcalcium signalingBiochemistryArticleMice03 medical and health sciencesAdenosine TriphosphateNeural Stem CellsDownregulation and upregulationCell MovementGeneticsmedicineAnimalsCell Self RenewalProgenitor celllcsh:QH301-705.5Cells CulturedCalcium signalinglcsh:R5-920Gene Expression ProfilingastrocytesGap JunctionsCell DifferentiationCell BiologyAnatomyHypoxia (medical)strokeNeural stem cellDisease Models Animal030104 developmental biologymedicine.anatomical_structurelcsh:Biology (General)chemistryBrain InjuriesCalciummedicine.symptomFunction and Dysfunction of the Nervous Systemlcsh:Medicine (General)TranscriptomeNeurosciencenotchDevelopmental BiologyStem Cell Reports
researchProduct

Administration of all‐ trans retinoic acid after experimental traumatic brain injury is brain protective

2020

BACKGROUND AND PURPOSE: All‐trans retinoic acid (ATRA) is a vitamin A metabolite, important in the developing and mature brain. Pre‐injury ATRA administration ameliorates ischaemic brain insults in rodents. This study examined the effects of post‐traumatic ATRA treatment in experimental traumatic brain injury (TBI). EXPERIMENTAL APPROACH: Male adult mice were subjected to the controlled cortical impact model of TBI or sham procedure and killed at 7 or 30 days post‐injury (dpi). ATRA (10 mg kg−1, i.p.) was given immediately after the injury and 1, 2 and 3 dpi. Neurological function and sensorimotor coordination were evaluated. Brains were processed for (immuno‐) histological, mRNA and protei…

Male0301 basic medicineTraumatic brain injuryRetinoic acidTretinoinPharmacologyHippocampal formationHMGB1Mice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBrain Injuries TraumaticmedicineAnimalsInflammationPharmacologyMicrogliabiologybusiness.industryBrainmedicine.diseaseGranule cellResearch PapersAstrogliosis030104 developmental biologymedicine.anatomical_structurechemistryBlood-Brain BarrierApoptosisbiology.proteinbusiness030217 neurology & neurosurgeryBritish Journal of Pharmacology
researchProduct

Plasminogen activator inhibitor‐1 augments damage by impairing fibrinolysis after traumatic brain injury

2019

Objective Plasminogen activator inhibitor-1 (PAI-1) is the key endogenous inhibitor of fibrinolysis, and enhances clot formation after injury. In traumatic brain injury, dysregulation of fibrinolysis may lead to sustained microthrombosis and accelerated lesion expansion. In the present study, we hypothesized that PAI-1 mediates post-traumatic malfunction of coagulation, with inhibition or genetic depletion of PAI-1 attenuating clot formation and lesion expansion after brain trauma. Methods We evaluated PAI-1 as a possible new target in a mouse controlled cortical impact (CCI) model of traumatic brain injury. We performed the pharmacological inhibition of PAI-1 with PAI-039 and stimulation b…

Male0301 basic medicineTraumatic brain injurymedicine.medical_treatmentBrain damagePharmacologyLesionMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBrain Injuries TraumaticSerpin E2FibrinolysisAnimalsMedicineThrombusResearch ArticlesIndoleacetic Acidsbusiness.industryFibrinolysisBrainmedicine.diseaseMice Inbred C57BL030104 developmental biologyNeurologychemistryPlasminogen activator inhibitor-1Neurology (clinical)medicine.symptombusinessPlasminogen activator030217 neurology & neurosurgeryIntravital microscopyResearch ArticleAnnals of Neurology
researchProduct

Single intracerebroventricular progranulin injection adversely affects the blood–brain barrier in experimental traumatic brain injury

2021

Progranulin (PGRN) is a neurotrophic and anti-inflammatory factor with protective effects in animal models of ischemic stroke, subarachnoid hemorrhage, and traumatic brain injury (TBI). Administration of recombinant (r) PGRN prevents exaggerated brain pathology after TBI in Grn-deficient mice, suggesting that local injection of recombinant progranulin (rPGRN) provides therapeutic benefit in the acute phase of TBI. To test this hypothesis, we subjected adult male C57Bl/6N mice to the controlled cortical impact model of TBI, administered a single dose of rPGRN intracerebroventricularly (ICV) shortly before the injury, and examined behavioral and biological effects up to 5 days post injury (dp…

Male0301 basic medicinemedicine.medical_specialtySubarachnoid hemorrhageTraumatic brain injuryPrimary Cell Culture610 MedizinBlood–brain barrierOccludinBiochemistryNeuroprotectionMice03 medical and health sciencesCellular and Molecular NeuroscienceProgranulins0302 clinical medicineInternal medicine610 Medical sciencesBrain Injuries TraumaticmedicineAnimalsNeuroinflammationInjections IntraventricularTight Junction ProteinsBehavior AnimalMicrogliabiologybusiness.industrymedicine.diseaseRecombinant ProteinsMice Inbred C57BL030104 developmental biologymedicine.anatomical_structureEndocrinologyAnimals NewbornBlood-Brain BarrierAstrocytesbiology.proteinEncephalitisMicrogliabusiness030217 neurology & neurosurgeryNeurotrophin
researchProduct

RS1 (Rsc1A1) deficiency limits cerebral SGLT1 expression and delays brain damage after experimental traumatic brain injury

2018

Acute cerebral lesions are associated with dysregulation of brain glucose homeostasis. Previous studies showed that knockdown of Na+ -D-glucose cotransporter SGLT1 impaired outcome after middle cerebral artery occlusion and that widely expressed intracellular RS1 (RSC1A1) is involved in transcriptional and post-translational down-regulation of SGLT1. In the present study, we investigated whether SGLT1 is up-regulated during traumatic brain injury (TBI) and whether removal of RS1 in mice (RS1-KO) influences SGLT1 expression and outcome. Unexpectedly, brain SGLT1 mRNA in RS1-KO was similar to wild-type whereas it was increased in small intestine and decreased in kidney. One day after TBI, SGL…

Male0301 basic medicinemedicine.medical_specialtyTraumatic brain injuryGene ExpressionBrain EdemaBrain damageBiochemistryProinflammatory cytokineMice03 medical and health sciencesCellular and Molecular NeuroscienceSodium-Glucose Transporter 10302 clinical medicineInternal medicineCortex (anatomy)Brain Injuries TraumaticmedicineAnimalsGlucose homeostasisEye ProteinsBrain ChemistryCerebral CortexMice KnockoutGene knockdownKidneyMovement DisordersMicrogliabusiness.industrydigestive oral and skin physiologyBrainmedicine.diseaseUp-RegulationMice Inbred C57BL030104 developmental biologymedicine.anatomical_structureEndocrinologyCytokinesMicrogliamedicine.symptombusinessCell Adhesion Molecules030217 neurology & neurosurgeryJournal of Neurochemistry
researchProduct

Deficiency of Plasminogen Activator Inhibitor Type 2 Limits Brain Edema Formation after Traumatic Brain Injury

2019

Plasminogen activator inhibitor-2 (PAI-2/SerpinB2) inhibits extracellular urokinase plasminogen activator (uPA). Under physiological conditions, PAI-2 is expressed at low levels but is rapidly induced by inflammatory triggers. It is a negative regulator of fibrinolysis and serves to stabilize clots. In the present study, PAI-2 expression is upregulated 25-fold in pericontusional brain tissue at 6 h after traumatic brain injury (TBI), with a maximum increase of 87-fold at 12 h. To investigate a potentially detrimental influence of PAI-2 on secondary post-traumatic processes, male PAI-2-deficient (PAI-2-KO) and wild-type mice (WT) were subjected to TBI by controlled cortical impact injury. Br…

Male030506 rehabilitationmedicine.medical_specialtyTraumatic brain injuryBrain EdemaInflammationBlood–brain barrierMice03 medical and health sciences0302 clinical medicineInternal medicineBrain Injuries TraumaticPlasminogen Activator Inhibitor 2medicineExtracellularAnimalsMice KnockoutBrain edemaUrokinase Plasminogen Activatorbusiness.industrymedicine.diseaseMice Inbred C57BLEndocrinologymedicine.anatomical_structureNeurology (clinical)medicine.symptom0305 other medical sciencebusinessPlasminogen activator030217 neurology & neurosurgeryJournal of Neurotrauma
researchProduct

Skull Fractures Induce Neuroinflammation and Worsen Outcomes after Closed Head Injury in Mice

2020

The weight-drop model is used widely to replicate closed-head injuries in mice; however, the histopathological and functional outcomes may vary significantly between laboratories. Because skull fractures are reported to occur in this model, we aimed to evaluate whether these breaks may influence the variability of the weight-drop (WD) model. Male Swiss Webster mice underwent WD injury with either a 2 or 5 mm cone tip, and behavior was assessed at 2 h and 24 h thereafter using the neurological severity score. The expression of interleukin (IL)-6, IL-1β, tumor necrosis factor-α, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 genes was m…

Male030506 rehabilitationmedicine.medical_specialtyTraumatic brain injurySkull fractureMice03 medical and health sciencesTraumatic brain injury0302 clinical medicineNeuroinflammationSkull fractureHead Injuries ClosedBrain Injuries TraumaticWeight-drop modelmedicineAnimalsNeuroinflammationInflammationSkull Fracturesbusiness.industryOriginal Articlesmedicine.diseaseSurgeryDisease Models AnimalSkullmedicine.anatomical_structureClosed head injuryNeurology (clinical)0305 other medical sciencebusiness030217 neurology & neurosurgeryJournal of Neurotrauma
researchProduct

Delayed inhibition of angiotensin II receptor type 1 reduces secondary brain damage and improves functional recovery after experimental brain trauma*

2011

OBJECTIVE:: To investigate the regulation of the cerebral renin-angiotensin system and the effect of angiotensin II receptor type 1 inhibition on secondary brain damage, cerebral inflammation, and neurologic outcome after head trauma. DESIGN:: The expression of renin-angiotensin system components was determined at 15 mins, 3 hrs, 6 hrs, 12 hrs, and 24 hrs after controlled cortical impact in mice. Angiotensin II receptor type 1 was inhibited using candesartan (0.1, 0.5, 1 mg/kg) after trauma to determine its effect on secondary brain damage, brain edema formation, and inflammation. The window of opportunity was tested by delaying angiotensin II receptor type 1 inhibition for 30 mins, 1 hr, 2…

MaleAngiotensin receptorTraumatic brain injuryPoison controlInflammationBrain damagePharmacologyCritical Care and Intensive Care MedicineRenin-Angiotensin SystemMicemedicineAnimalsAngiotensin II receptor type 1biologybusiness.industryRecovery of Functionmedicine.diseaseMice Inbred C57BLNitric oxide synthaseCandesartanBrain InjuriesAnesthesiabiology.proteinmedicine.symptombusinessAngiotensin II Type 1 Receptor Blockersmedicine.drugCritical Care Medicine
researchProduct

Cellular localization of mGluR3 and mGluR5 mRNAs in normal and injured rat brain

2007

Abstract In order to understand the role of metabotropic glutamate receptors (mGluRs) in the brain, it is important to know how the mGluRs are differentially expressed among the different cell types. At present, the cellular expression of mGluR3 and mGluR5 has been mostly studied in terms of proteins with observations suggesting the expression of both mGluR3 and mGluR5 in neuronal and in glial cells. In order to verify the brain cell type-expressing mGluR3 and mGluR5 mRNAs, both in normal and injured brain, we performed a double labeling analysis, by in situ hybridization for mGluR3 or mGluR5 mRNA and immunohistochemistry for specific cellular markers. This approach allowed us to find mGluR…

MaleCell typeReceptor Metabotropic Glutamate 5In situ hybridizationHippocampal formationBiologyReceptors Metabotropic GlutamateSettore BIO/09 - Fisiologiamental disordersmedicineAnimalsRNA MessengerRats WistarMolecular BiologyCellular localizationIn Situ HybridizationNeuronsGeneral NeuroscienceGlutamate receptorBrainImmunohistochemistryOligodendrocyteCell biologyRatsmedicine.anatomical_structurenervous systemBrain InjuriesNeurogliaNeurology (clinical)NeuroscienceNeurogliaDevelopmental BiologyAstrocyte
researchProduct

Novel complement C1 inhibitor BSF468248 does not improve brain damage after cortical vein occlusion

2003

BSF468248 is a novel potent complement C1 inhibitor. To determine whether BSF468248 is effective against focal cerebral ischemia, we evaluated the change of cerebral blood flow (CBF) and infarction volume using a photochemically-induced cortical vein occlusion model in rats in blind studies. In 22 Wistar rats, two adjacent cortical veins were occluded by photochemical thrombosis and fiberoptic illumination under controlled anesthesia and ventilation. Just after the occlusion, BSF468248 or physiological saline was administrated. In the low-dose study, a treatment group (n = 7) was administered BSF468248 1 mg/kg bolus and 1 mg/kg continuously for 30 min. The same volume of saline was given to…

MaleCerebral veinsPhotochemistrymedicine.medical_treatmentComplement C1 Inactivator ProteinsRats Sprague-DawleyBolus (medicine)OcclusionmedicineAnimalsRats WistarInfusions IntravenousSalineCerebral Cortexbusiness.industryCerebral InfarctionBlood flowCortical Veinmedicine.diseaseCerebral VeinsThrombosisRatsDisease Models AnimalTreatment OutcomeCerebral blood flowRegional Blood FlowBrain InjuriesCerebrovascular CirculationAnesthesiaIntracranial ThrombosisbusinessOligopeptidesMethods and Findings in Experimental and Clinical Pharmacology
researchProduct